המליברה 150 מגמל ישראל - עברית - Ministry of Health

המליברה 150 מגמל

roche pharmaceuticals (israel) ltd - emicizumab - תמיסה להזרקה - emicizumab 150 mg / 1 ml - emicizumab

המליברה 30 מגמל ישראל - עברית - Ministry of Health

המליברה 30 מגמל

roche pharmaceuticals (israel) ltd - emicizumab - תמיסה להזרקה - emicizumab 30 mg / 1 ml - emicizumab

טמיפלו 75 מג ישראל - עברית - Ministry of Health

טמיפלו 75 מג

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

טמיפלו 75 מג ישראל - עברית - Ministry of Health

טמיפלו 75 מג

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

טמיפלו 75 מג ישראל - עברית - Ministry of Health

טמיפלו 75 מג

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 75 mg - oseltamivir - oseltamivir - - treatment of uncomplicated acute illness due to influenza infection in adults patients and patients who weigh more than 40 kg who have been symptomatic for no more than 2 days. - post exposure prevention in adults and patients who weight more the 40 kg following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults patients and patients who weigh more than 40 kg.

טמיפלו 30 מג ישראל - עברית - Ministry of Health

טמיפלו 30 מג

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 30 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.

טמיפלו 45 מג ישראל - עברית - Ministry of Health

טמיפלו 45 מג

roche pharmaceuticals (israel) ltd - oseltamivir as phosphate - קפסולות - oseltamivir as phosphate 45 mg - oseltamivir - oseltamivir - treatment of influenza : treatment of uncomplicated acute illness due to influenza infection in adults and children 1 year of age or older who have been symptomatic for no more than 2 days. prophylaxis of influenza : post exposure prevention in adults and children 1 year of age or older patients following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. the appropriate use of tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. in exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains and a pandemic situation) seasonal prevention could be considered in adults and children 1 year of age or older.

טרסבה 150 מג ישראל - עברית - Ministry of Health

טרסבה 150 מג

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

טרסבה 100 מג ישראל - עברית - Ministry of Health

טרסבה 100 מג

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

סלספט 250 מג ישראל - עברית - Ministry of Health

סלספט 250 מג

roche pharmaceuticals (israel) ltd - mycophenolate mofetil - קפסולות - mycophenolate mofetil 250 mg - mycophenolic acid - mycophenolic acid - prophylaxis of rejection in renal allograft recepients, and in patients reciving allogenic cardiac transplants. cellcept should be used concomitantly with cyclosporin and corticosteroids.allogenic hepatic transplant.